HomeCompareGMEV vs JNJ

GMEV vs JNJ: Dividend Comparison 2026

GMEV yields 4000000.00% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GMEV wins by $4.994481689239762e+42M in total portfolio value
10 years
GMEV
GMEV
● Live price
4000000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.994481689239762e+42M
Annual income
$4,994,236,078,782,737,000,000,000,000,000,000,000,000,000,000,000.00
Full GMEV calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — GMEV vs JNJ

📍 GMEV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodGMEVJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, GMEV + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
GMEV pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

GMEV
Annual income on $10K today (after 15% tax)
$340,000,000.00/yr
After 10yr DRIP, annual income (after tax)
$4,245,100,666,965,326,000,000,000,000,000,000,000,000,000,000,000.00/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, GMEV beats the other by $4,245,100,666,965,326,000,000,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of GMEV + JNJ for your $10,000?

GMEV: 50%JNJ: 50%
100% JNJ50/50100% GMEV
Portfolio after 10yr
$2.497240844619881e+42M
Annual income
$2,497,118,039,391,368,600,000,000,000,000,000,000,000,000,000,000.00/yr
Blended yield
100.00%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

GMEV
No analyst data
Altman Z
-122.6
Piotroski
5/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

GMEV buys
0
JNJ buys
0
No recent congressional trades found for GMEV or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricGMEVJNJ
Forward yield4000000.00%2.13%
Annual dividend / share$2.00$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28%
Portfolio after 10y$4.994481689239762e+42M$30.3K
Annual income after 10y$4,994,236,078,782,737,000,000,000,000,000,000,000,000,000,000,000.00$4,689.40
Total dividends collected$4.994465620575748e+42M$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: GMEV vs JNJ ($10,000, DRIP)

YearGMEV PortfolioGMEV Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$400,010,700$400,000,000.00$10,592$272.30+$400.00MGMEV
2$14,954,099,039,486$14,953,671,028,037.38$11,289$357.73+$14954099.03MGMEV
3$522,475,570,786,797,700$522,459,569,900,825,500.00$12,123$472.89+$522475570786.79MGMEV
4$17,060,387,015,284,700,000,000$17,059,827,966,423,956,000,000.00$13,141$629.86+$17060387015284700.00MGMEV
5$520,629,757,399,644,800,000,000,000$520,611,502,785,538,400,000,000,000.00$14,408$846.81+$520629757399644831744.00MGMEV
6$14,848,629,939,995,690,000,000,000,000,000$14,848,072,866,155,271,000,000,000,000,000.00$16,021$1,151.60+$1.4848629939995692e+25MGMEV
7$395,786,651,827,842,740,000,000,000,000,000,000$395,770,763,793,806,900,000,000,000,000,000,000.00$18,122$1,588.22+$3.9578665182784276e+29MGMEV
8$9,859,464,902,403,675,000,000,000,000,000,000,000,000$9,859,041,410,686,219,000,000,000,000,000,000,000,000.00$20,930$2,228.20+$9.859464902403675e+33MGMEV
9$229,542,483,200,980,940,000,000,000,000,000,000,000,000,000$229,531,933,573,535,350,000,000,000,000,000,000,000,000,000.00$24,792$3,191.91+$2.2954248320098093e+38MGMEV
10$4,994,481,689,239,762,000,000,000,000,000,000,000,000,000,000,000$4,994,236,078,782,737,000,000,000,000,000,000,000,000,000,000,000.00$30,274$4,689.40+$4.994481689239762e+42MGMEV

GMEV vs JNJ: Complete Analysis 2026

GMEVStock

GME Innotainment, Inc. engages in artist management and event management businesses in Hong Kong, China, and the Asia-Pacific. The company's activities include movie production, distribution, and licensing; music production; talent acquisition and management; concert and event management; and social media management for artists and celebrities. It offers artist management services to adolescents and young adults, brand owners, and institutional customers; and entertainment services to cinema-goers, movie investors, cinema circuits, and broadcasting channel providers. The company was formerly known as Great China Mania Holdings, Inc. and changed its name to GME Innotainment, Inc. in June 2015. GME Innotainment, Inc. was incorporated in 1983 and is headquartered in Hong Kong, Hong Kong.

Full GMEV Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this GMEV vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

GMEV vs SCHDGMEV vs JEPIGMEV vs OGMEV vs KOGMEV vs MAINGMEV vs ABBVGMEV vs MRKGMEV vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.